RxDoctor Payments Data

Jacob Kanter, MD

Ophthalmology · Baltimore, MDNPI 1710448162

Payments from drug & device makers

$2,140in general payments, 2019–2025

Across 18 payments — averaging $118.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$445
  • NEW World Medical,inc.$291
  • Alimera Sciences, Inc.$252
  • Sight Sciences, Inc.$53
  • Eyepoint US, Inc.$34

What the payments were for

  • Travel & lodging$90442%
  • Food & beverage$1,13553%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon4$1,065
AbbVie(2 entities)6$445
NEW World Medical,inc.3$291
Alimera Sciences, Inc.2$252
Sight Sciences, Inc.2$53
Eyepoint US, Inc.1$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,140 in reported general payments places this provider in the 60th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$222,499
Medicare patients
686
Services billed
1,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate161$85,843
LumiganBimatoprost127$75,207
Travoprost115$31,520
CombiganBrimonidine Tartrate/Timolol53$28,946
Latanoprost1,850$28,255
Brimonidine Tartrate488$25,470
VyzultaLatanoprostene Bunod34$20,695
Prednisolone Acetate502$19,745
RocklatanNetarsudil Mesylat/Latanoprost28$18,933
RestasisCyclosporine15$18,035
Dorzolamide-TimololDorzolamide/Timolol/Pf112$16,560
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat715$15,319
Brinzolamide54$13,227
SimbrinzaBrinzolamide/Brimonidine Tart42$12,206
Alphagan PBrimonidine Tartrate32$11,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$445$133,658227 claims
AlconSimbrinza$1,065$12,20642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →